30
Participants
Start Date
February 15, 2025
Primary Completion Date
February 15, 2027
Study Completion Date
February 15, 2028
TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell
Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
Fludarabine
Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
Cyclophosphamide
Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
RECRUITING
Biotherapeutic Department of Chinese PLA General Hospital, Beijing
NOT_YET_RECRUITING
Department of Hematology, Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Department of Hematology, Tianjin First Central Hospital, Tianjin
Peking University
OTHER
Chinese PLA General Hospital
OTHER